Indianapolis-based FAST Diagnostics gets funding from BioCrossroads’ seed fund

Indianapolis-based FAST Diagnostics has received a second round of funding from BioCrossroads’ Indiana Seed Fund.

The $150,000 will help FAST refine its tool to treat acute kidney injury
and to prepare for large, preclinical studies.

Previously, the $6 million
BioCrossroads fund invested $380,000 toward initial commercialization efforts.

“The lackluster capital market has proven to be a challenge,” said Joe Muldoon, FAST’s CEO.

BioCrossroads CEO David Johnson said FAST has continued to meet key milestones and has successfully
built partnerships with other companies and with colleges, including Rose-Hulman Institute of Technology,
Indiana University and Purdue University.

FAST has been buoyed by additional
funding, including $200,000 from the Purdue Research Foundation and a $1.1 million grant from the National
Institutes of Health.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.